(MENAFN- PR Newswire)

• AMA assigns CPT codes 0992T and 0993T to Caristo's CaRi-Heart® AI-powered analysis of perivascular fat and cardiovascular risk, which are included in the 2026 CPT® Codebook
• New CPT codes mark a major step toward making CaRi-Heart technology available in everyday clinical care in the U.S.

STAMFORD, Conn., Sept. 23, 2025 /PRNewswire/ -- Caristo Diagnostics , a global leader in AI-powered heart disease detection, today announced that the American Medical Association (AMA) has formally assigned Category III Current Procedural Terminology (CPT^®) codes 0992T and 0993T for AI-powered analysis of perivascular fat and cardiovascular risk, the foundational capability behind Caristo's flagship CaRi-Heart technology.

CPT codes are standardized numeric codes used in medical billing and coding to identify and describe medical services and procedures. The official code descriptions for the CaRi-Heart technology were published on the AMA CPT website on July 1, 2025, and the codes are now included in the 2026 CPT Codebook :

• 0992T: Noninvasive assessment of cardiac risk derived from augmentative software analysis of perivascular fat without concurrent computed tomography (CT) scan of the heart, including patient-specific clinical factors, with interpretation and report by a physician or other qualified health care professional
• 0993T: Noninvasive assessment of cardiac risk derived from augmentative software analysis of perivascular fat with concurrent computed tomography scan of the heart, including patient-specific clinical factors, with interpretation and report by a physician or other qualified health care professional

These latest updates build on the AMA CPT Editorial Panel's February 2025 decision to approve new Category III CPT codes for CaRi-Heart technology. With code assignment and publication now complete, Caristo has achieved a critical milestone in path to U.S. clinical adoption, reimbursement, and payer engagement. This brings the technology another step closer to enabling cardiologists to integrate AI-powered coronary inflammation analysis into routine practice, accelerating its journey from research to real-world impact.

A 2024 landmark Lancet publication Caristo's technology can reveal hidden, high-risk markers of coronary artery disease (CAD) progression - predicting heart attacks up to a decade before they strike. CaRi-Heart uses advanced AI to analyze perivascular fat captured in standard coronary CT angiography (CCTA) scans. The technology reveals hidden coronary inflammation-a powerful but previously invisible predictor of heart attacks. Its proprietary FAI-ScoreTM and CaRi-Heart Risk score give clinicians and patients a personalized assessment of cardiac mortality risk, informing earlier and more targeted treatment decisions even when patients receive "normal" results from tests such as calcium score, high sensitivity CRP (hsCRP), and quantitative plaque analysis.

"This is a huge leap forward in the fight against heart disease, and a major validation that AI-powered coronary inflammation analysis belongs in routine care," said Frank Cheng, CEO of Caristo Diagnostics. "With CPT approval, assignment, and publication, we are laying the foundation for a future where every at-risk American has access to precision risk assessment, moving heart care from late-stage intervention to truly preventive medicine."

The CaRi-Heart technology is currently limited to research use in the United States, and its newly approved CPT codes will become effective on January 1, 2026.

In addition to Cari-Heart technology, Caristo also offers CaRi-Plaque^TM analysis for plaque and stenosis quantification. The CaRi-Plaque technology was granted FDA 510(k) clearance and is supported by a Category I CPT code which will become effective on January 1, 2026.

About Caristo Diagnostics

Caristo Diagnostics is a global leader in AI-powered heart disease detection. A spinout from the University of Oxford, Caristo's award-winning technology is transforming cardiovascular care by identifying hidden heart attack risks before symptoms appear. Backed by leading hospitals and scientists, Caristo is on a mission to save lives through early detection and personalized prevention. For more information, visit caristo . Find Caristo online on LinkedIn , YouTube, and X .

Logo -

SOURCE CARISTO DIAGNOSTICS

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN23092025003732001241ID1110098622